In developed countries, most people living with HIV/AIDS are treated with costly brand single-tablet regimens. Given the economic impact, French guidelines recommend using generic antiretroviral therapy when possible to decrease antiretroviral therapy costs. We aimed to study HIV-infected patients’ acceptability to switch from a brand single-tablet regimens [abacavir/lamivudine/dolutegravir (Triumeq^®) or emtricitabine/tenofovir disoproxil fumarate/rilpivirine (Eviplera^®)] to a treatment comprising of two pills: one is a fixed-dose generic combination of 2 Nucleoside Analogs and the second tablet is the third antiretroviral. This study was a prospective observational study in a French hospital. During their follow-up, patients on stable single-tablet regimens were made aware of the possible cost-saving. They were questioned about their willingness and barriers accepting the substitution. Participants chose between the two regimens, either to remain on single-tablet regimens or switch to the de-simplified regimen. Six months later, a second survey was given to the patient who chose to de-simplify and HIV viral load was controlled. The study included 98 patients: 60 receiving emtricitabine/tenofovir disoproxil fumarate/rilpivirine (Eviplera^®) and 38 on abacavir/lamivudine/dolutegravir (Triumeq^®). Forty-five patients accepted the de-simplified treatment, 37 refused and 16 were undecided and followed the decision offered by their physician. The main reason for unwillingness to switch is the number of pills (77.3%). In multivariate model analysis, male patients (p = 0.001) who have taken antiretroviral therapy for over 20 years (p = 0.04) and who retrieve their treatment in their community hospital (p = 0.03) are more likely to accept the switch. Fifty-one patients accepted to replace their single-tablet regimens and six months later, the majority was satisfied; only four returned to single-tablet regimens because of suspected side effects. Half of the people living with HIV/AIDS in our cohort accepted to switch from brand single-tablet regimens to a two-tablet regimen containing generic drugs within a process that emphasizes health expenditure savings.

在发达国家，大多数艾滋病毒/艾滋病感染者都接受了昂贵的品牌单片疗法。考虑到经济影响，法国指南建议尽可能使用通用抗逆转录病毒疗法，以降低抗逆转录病毒疗法的费用。我们的目的是从一个品牌的单片剂方案[阿巴卡韦/拉米夫定/ dolutegravir（Triumeq研究艾滋病毒感染的患者可接受到开关^®）或恩曲他滨/富马酸替诺福韦酯/利匹韦林（Eviplera ^®）]由两种药组成的疗法：一种是2种核苷类似物的固定剂量通用组合，第二种是第三种抗逆转录病毒药物。这项研究是一家法国医院的前瞻性观察性研究。在随访过程中，使患者采用稳定的单片治疗方案可以节省成本。他们被问及接受替代品的意愿和障碍。参加者在两种治疗方案之间进行选择，要么继续使用单片治疗方案，要么转向简化治疗方案。六个月后，对选择简化治疗并控制了HIV病毒载量的患者进行了第二次调查。该研究包括98名患者：60接受恩曲他滨/富马酸替诺福韦酯/利匹韦林（Eviplera ^®）和38上阿巴卡韦/拉米夫定/ dolutegravir（Triumeq ^®）。四十五名患者接受了简化治疗，其中三十七名患者拒绝接受治疗，十六名患者仍未决定，他们遵循了医生的决定。不愿意换药的主要原因是吃药的人数（77.3％）。在多变量模型分析中，接受抗逆转录病毒治疗超过20年（p = 0.04）并在社区医院接受治疗的男性患者（p = 0.001）（p = 0.03）更可能接受转换。51名患者接受替代单片治疗，六个月后，大多数患者感到满意。由于怀疑有副作用，只有四次返回单片治疗方案。